19 results about "Ferroportin" patented technology

The invention provides an anti-anemia traditional Chinese medicine composition as well as a preparation method and application thereof. The anti-anemia traditional Chinese medicine composition is prepared from lithocarpus litseifolius, fructus gardeniae and rhizoma gastrodiae. The main active component dihydrochalcone (such as phlorizin, trilobatin, phloretin and the like) of lithocarpus litseifolius can improve iron metabolism by regulating a hepcidin-iron transporter axis; gardenoside in gardenia can target the liver to optimize iron distribution, and gastrodia elata polysaccharide can regulate immunity and improve the marrow microenvironment; the three forms a full-chain regulation and control network of intestinal tract iron absorption, liver iron utilization and bone marrow hematopoiesis microenvironment together, and the anti-anemia effect is enhanced in multiple dimensions.

The invention relates to the use of ferroportin inhibitor compounds of the general formula (I) for treating transfusion-dependent β-thalassemia.

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and / or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

The invention relates to the technical field of antitumor drugs, and particularly discloses application and a composition of an iron transporter inhibitor (VIT-2763). The invention provides an application of an iron transporter inhibitor VIT-2763 in preparation of a medicine for preventing and treating tumor metastasis. The iron transporter inhibitor VIT-2763 can obviously inhibit liver metastasis of colorectal cancer and has the potential of being used as a medicine for resisting liver metastasis of colorectal cancer. Meanwhile, the invention further provides a composition for resisting colorectal cancer liver metastasis, the composition comprises the iron transporter inhibitor VIT-2763 and oxaliplatin, and when the iron transporter inhibitor VIT-2763 and the oxaliplatin are combined for use, the drug resistance of colorectal cancer cells to the oxaliplatin can be improved, the sensitivity of liver metastatic colorectal cancer cells to the oxaliplatin is remarkably improved, and the curative effect is good. The treatment effect of resisting colorectal cancer liver metastasis is synergistically enhanced, and the technical problem that an existing treatment means lacks a specific intervention means for colorectal cancer liver metastasis is solved.

The present invention relates to a matriptase-2 (MT2) inhibitor, a TMPRSS6 inhibitor, a ferroportin blocker, or a hepcidin enhancer. In particular, the present invention relates to the use of compounds capable of reducing at least one of the following: systemic iron levels, transferrin saturation (Tsat), non-transferrin-bound iron (NTBI), and unstable plasma iron (LPI). This may occur by inhibiting the expression of a target gene, where the target gene may be a transmembrane protease, serine 6 (TMPRSS6). Furthermore, the present invention relates to compositions comprising the above compounds, and methods of using such compounds and / or compositions. Such use may include therapeutic use, for example, to reduce iron overload and prevent iron-related toxicity, before, during, or after chemotherapy pretreatment, stem cell transplantation, and engraftment.

The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and / or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption, and / or iron overload.

Hepcidin is an hyposideremic hormone made primarily by the liver. To address the role of hepcidin made specifically by the intestine in lowering serum iron, the inventors generated transgenic mice overexpressing the peptide specifically in this tissue. These mice exhibit, at one month of age, a severe hyposideremia, along with decreased haematological indices and hair loss. Mechanistically, they showed that intestinal hepcidin made by the transgenic mice had no effect on intestinal ferroportin, but, in contrast, induced a striking down-regulation of Divalent Metal Transporter 1 (DMT1) protein at the apical side of the enterocyte. Intestinal hepcidin can be produced in the apical side suggesting the direct role of apical hepcidin on DMT1. To confirm the therapeutic capacity of hepcidin on regulation of DMT1, the inventors developed probiotics (engineered recombinant lactic acid bacteria), capable of delivering hepcidin directly into the lumen of the intestine. They orally administrated daily these probiotics in hemochromatosis mice model, after 28 days of treatments they observe a decrease of iron overload. Thus, the present invention relates to a method for preventing or treating an iron overload associated disease in a subject in need thereof, comprising administering locally in the gut of the subject hepcidin.

The present invention relates to compounds of the formula and their pharmaceutically acceptable salts, solvates, hydrates, or polymorphs for use in the treatment of hereditary hemochromatosis. [Formula 1] TIFF2026522008000015.tif27159

The present invention relates to compounds of the formula as well as pharmaceutically acceptable salts, solvates, hydrates or polymorphs thereof for use in the treatment of hereditary hemochromatosis.

The present invention relates to the use of ferroportin inhibitor compounds of general formula (I) for treating myelodysplastic syndromes (MDS). JPEG2024504349000030.jpg30123

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and / or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

The present invention relates to a novel process for the preparation of compounds of formula (I) and pharmaceutically acceptable salts thereof, which are suitable for use as drugs for the prevention and / or treatment of diseases caused by hepcidin deficiency or iron metabolism disorders leading to increased iron levels or increased iron absorption, including iron overload, thalassemia, sickle cell disease and hemochromatosis.

The invention relates to a novel compound of the general formula (IA) as defined in the application and a pharmaceutical composition comprising the compound for use as a medicament, in particular for use as a ferroportin inhibitor, more particularly for use in the prophylaxis or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption or iron overload.

The invention relates to the use of the compound of the formula (I) and pharmaceutically acceptable salts thereof, which acts as ferroportin inhibitor, for the use in the treatment of lupus nephritis and of pathophysiological symptoms and conditions associated therewith or deriving therefrom or being associated with systemic lupus erythematosus.

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and / or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

The invention relates to a new process for preparing compounds of the formula (I) and pharmaceutically acceptable salts thereof, which act as ferroportin inhibitors being suitable for the use as medicaments in the prophylaxis and / or treatment of diseases caused by a lack of hepcidin or of iron metabolism disorders leading to increased iron levels or increased iron absorption, including iron overload, thalassemia, sickle cell disease and hemochromatosis.

The invention relates to the use of ferroportin inhibitor compounds of the general formula (I)for treating myelodysplastic syndromes (MDS).

To provide a new process for preparing ferroportin inhibitors.SOLUTION: A process for preparing a compound of formula (I), which comprises reacting a compound of formula (IM-3) with a compound of formula (RM-3).SELECTED DRAWING: None

The present invention relates to novel compounds of general formula (IA) as defined in the present application and pharmaceutical compositions comprising them and their use as medicaments, in particular for use as ferroportin inhibitors, more particularly for use in the prevention and / or treatment of diseases caused by a lack of hepcidin or disorders of iron metabolism leading to elevated iron levels or increased iron absorption and / or iron overload. JPEG2025535398000130.jpg36129